Background
Idiopathic Pulmonary Fibrosis (IPF) is a chronic lung disease, characterized by poor prognosis, primarily affecting older individuals [
1]. IPF pathogenesis is attributed to an accelerated apoptosis of Type-II pneumocytes coupled to an aberrant wound healing process, involving defective re-epithelization, abnormal fibroblast/myofibroblast apoptosis and excessive accumulation of extracellular matrix components [
2]. Age associated changes, including telomere attrition, defective autophagy, mitochondrial dysfunction and cell senescence, are linked to IPF pathogenesis [
3].
Mitochondria drive ATP production through oxidative phosphorylation (OXPHOS) and they represent the major generator of reactive oxygen species (ROS). In the last decade, it has become evident that cellular metabolism is intertwined with immune responses while, mitochondria activity largely shapes immune cell functions [
4]. Mitochondrial function declines with age, resulting in morphological alterations, loss of cristae, reduced mitochondria respiratory chain (MRC) function and increased ROS production which is associated with mtDNA damage, fueling a vicious cycle of mitochondria impairment [
5]. Mitochondrial homeostasis is essential for cellular health, and is tightly regulated by biogenesis and degradation/recycling [
6]. PTEN-induced kinase 1 (PINK1) and E3 ubiquitin ligase (Parkin - encoded by PARK2 gene) represent key effector proteins of mitophagy, a selective form of macroautophagy, participating in the clearance of oxidized and damaged mitochondria [
7].
Accumulation of damaged mitochondria is associated with IPF and the aging lung [
3,
8,
9]. PINK1 deficiency and insufficient mitophagy in alveolar epithelial cells leads to increased mitochondrial damage and progression of fibrosis [
10]. Conversely, PINK1 upregulation in mice contributes to elimination of fibrosis [
11]. PINK1 decrease in fibrotic foci in IPF, and TGF-β treatment of lung fibroblasts lowers PINK1 and increases ROS levels [
12]. PARK2 knockdown induces mitochondrial damage, increases mtROS production and promotes fibrosis through enhancement of apoptotic resistant phenotype of fibroblasts and myofibroblast differentiation [
13]. MtROS is linked to mtDNA damage and evidence from a recent study in IPF showed a higher mutation rate in mitochondrial tRNA, probably affecting intra-mitochondrial translation [
14]. Importantly, a widely used antidiabetic medication, metformin, ameliorated lung fibrosis in mice through beneficial effects on mitochondria, highlighting their pathogenetic role in pulmonary fibrosis [
15].
Lung macrophages are a fluctuating and diverse population with a central role in inflammation, host defense, and tissue homeostasis [
16]. It is well documented that macrophages within the lung orchestrate the downstream progression and maintenance of fibrosis [
17]. A substantial expansion of macrophages in distal lung tissue is observed in IPF and a profibrotic macrophage population that appears in the lung during the development of fibrosis is currently under investigation [
18,
19]. ROS production is required for the alternative activation of macrophages and can be attenuated by ROS inhibitors including N-acetyl-cysteine [
20]. Interestingly, generation of mtROS from AMs has been causatively related to the development of asbestos-induced pulmonary fibrosis [
21]. Mitochondria homeostasis in IPF AMs is not well characterized and in this study we sought to evaluate mitochondrial ROS levels, morphology, and mitophagy in AMs isolated from BAL in IPF patients.
Materials and methods
Patients
Seventy one (71) patients were prospectively enrolled in the Department of Thoracic Medicine, University Hospital of Heraklion, Crete, Greece from 2014 to 2018. Fifty two [52] patients with IPF and nineteen [19] healthy controls underwent bronchoscopy and Bronchoalveolar Lavage Fluid (BAL) was obtained.
IPF group: The diagnosis of IPF was based on ATS/ERS criteria or on multidisciplinary discussion [
22]. Bronchoscopy was performed in treatment naive IPF patients as a part of the diagnostic approach.
All patients were evaluated within 1 month from bronchoscopy, with complete pulmonary function tests (PFTs). Lung volumes (forced expiratory volume in 1 sec – FEV1, forced vital capacity – FVC), using the helium-dilution technique and diffusion capacity (DLco, corrected for haemoglobin) using the single breath technique. The computerized system (Jaeger 2.12; MasterLab, Würzburg, Germany) was used and predicted values were obtained from the standardized lung function testing of the European Coal and Steel Community, Luxembourg (1993).
Control group: Control subjects were patients undergoing bronchoscopy for the investigation of haemoptysis and BAL sampling was performed at least 6 weeks following hospitalization. No signs of infection, ILD abnormalities or putative malignant lesions in the CT scans were observed. Furthermore, during bronchoscopy, no malignant lesions in the airways were observed, or abnormal mucus secretion was noted. BAL cellularity and differential BAL cell count were within the normal range. Additionally, BAL samples testing positive for bacteria growth were excluded. Since controls were healthy subjects no PFTs were performed.
Patients were classified as non-smokers, current smokers or former smokers (defined as having smoked a minimum of one cigarette a day for a minimum of 1 year, stopping at least 6 months before presentation).
Demographic data, pulmonary function tests, and BAL differential cell count are summarised in Table
1.
Table 1
Clinicopathological characteristics of all subjects included in the study. Values are expressed as median with range
Number | 19 | 52 |
Gender (Male/Female) | 10/9 | 39/13 |
Packyears | 30(0–100) | 26(0–150) |
Non smokers | 1 | 18 |
Former smokers | 3 | 27 |
Current smokers | 15 | 7 |
Age (years) | 62(40–74) | 74(56–84) |
Macrophages | 91(74–99) | 87.25(49–97) |
Lymphocytes | 5(0.5–25) | 5.37(0.25–45) |
Neutrophils | 1(0–8.8) | 4.75(0.25–45) |
Eosinophils | 0(0–1.25) | 1(0–7) |
FVC | | 85 ± 20 |
FEV1 | | 93 ± 18 |
FEV1/FVC | | 85.5 ± 5.8 |
TLC | | 76 ± 14 |
DLco | | 57 ± 19.5 |
Kco | | 87 ± 20 |
BAL cell isolation and determination of cellular composition
Bronchoalveolar Lavage (BAL) was obtained as previously reported [
23]. In brief, BAL was obtained from all patients at room temperature. A flexible bronchoscope was wedged into a sub-segmental bronchus of a predetermined region of interest based on radiographical findings. A BAL technique was performed by instilling a total of 180 ml of normal saline in 60-mL aliquots, each retrieved by low suction.
The BAL samples were subsequently kept on ice and were processed within 2 h of collection. Samples were filtered through sterile 70 nm cell strainers (BD) and centrifuged at 1500 rpm for 5 min at 4
οC. Cell pellets were washed and re-suspended with cold PBS. Total cell count and cell viability were subsequently assessed using Trypan blue (ICN). Differential cell population count was analysed following May-Grunewald-Giemsa staining as previously described [
24].
BAL cell isolation and AM culture
In order to study alveolar macrophages, by immune fluorescence or western blot, we enriched their population by pre-culture on glass slides or plastic dishes respectively, followed by washing of non-adherent cells such as lymphocytes, eosinophils and neutrophils, minor components of the BAL cell population. The remaining attached cell population comprises of macrophages and monocytes from the alveolar space. 0.5 million freshly isolated BAL cells were cultured in 24 well plates in DMEM (Biosera) growth media supplemented with 2% FCS (Biosera) and penicillin-streptomycin in a humidified incubator at 37 °C containing 5% CO2 for 1 h, with subsequent washes to remove non-adherent cells, allowing enrichment for alveolar macrophages/ monocytes.
BAL cell surface marker expression analysis
0.5 million freshly isolated BAL cells were resuspended in PBS, 2% FCS and 2 mM EDTA buffer and labelled with pan-leucocyte marker CD45-FITC (#IQP-124F, IQProducts), macrophage/DC marker CD11c-PE-Cy5 (#301610, Biolegend), or CD45-FITC, monocyte marker CD14-PE-Cy5 (#A07765, IOTest, Beckman Coulter). CD163-PE-Cy7 (#333614, Biolegend) and appropriate Isotype controls. Data were acquired with Beckman Coulter flow cytometer and analyzed with FlowJo 8.7 (Treestar, Ashland, OR).
Mitochondrial ROS measurement
Mitochondrial ROS was measured by MitoSOX™Red (Invitrogen) staining. MitoSOX™red is targeted to mitochondria in live cells and is readily oxidized by superoxide reactive oxygen species. Initially, the staining of oxidized mitochondria with MitoSOX following treatment with hydrogen peroxide (H
2O
2) was assessed. A549 cells, a non-small cell lung cancer (NSCLC)-derived human alveolar epithelial cell line, were treated with 1000 μM H
2O
2 and the characteristic staining for the mitochondrial network in the cytoplasm was observed which was further enhanced upon H
20
2 treatment and mitochondria oxidation (Additional file
1: Figure S1a). Secondly, flow cytometry analysis of MitoSOX staining was tested on of THP1 human monocytes. THP1 cells showed a strong fluorescent MitoSOX signal (Additional file
1: Figure S1b) which was greatly enhanced following 1000 μM H
2O
2 treatment. Necrotic and apoptotic cells were expected to contain oxidized mitochondria and since H
2O
2 treatment is known to induce apoptosis, thus Propidium Iodide (PI) staining was analysed in parallel which allowed for the exclusion of the MitoSOX positive necrotic/apoptotic population from the analysis of the alive MitoSOX positive cells (Additional file
1: Figure S1b). A high proportion of MitoSOX positive cells upon H
2O
2 treatment was present despite the exclusion of the PI negative cell population (Additional file
1: Figure S1b) and the same PI positive population exclusion strategy was used subsequently in human BAL cells.
0.5 million freshly isolated BAL cells were cells were resuspended in RPMI-1640 supplemented with 2% FCS were stained with MitoSOX Red at a final concentration of 5 μM and CD45-FITC for 10 min at 37 °C. For FL-2, MitoSOX staining quantification, alveolar macrophages populations was selected according to high side scatter SSC
high and CD45
+(Additional file
1: Figure S1c and d). Propidium Iodide (PI) was added to cells not previously stained with MitoSOX at a final concentration of 1 ng/ml, for 5 min immediately before flow cytometry analysis, for the detection of necrotic/apoptotic cells. A CD45-FITC stained control for each patient sample served as the unstained control sample for subsequent quantifications. PI staining allowed the exclusion of apoptotic/necrotic cells. Despite the PI exclusion gating strategy, a small percentage of Propidium Iodide (PI) positive cells was still among the MitoSOX positive analysed population and it was subtracted from the MitoSOX positive cell percentage during quantifications shown in Fig.
2b.
The percentage of MitoSOX positive cells was determined by the percent of cells showing FL-2 fluorescence higher than the unstained control, followed by subtraction of the FL-2 PI positive percentage of cells. Relative mean fluorescence intensity (MFI) was calculated by normalizing the MFI of the FL-2 channel/MitoSOX positive cells by the MFI of the FL-2 channel of the unstained cells since patient samples displayed wide ranges of autofluorescence. Data were acquired with Beckman Coulter flow cytometer and analyzed with FlowJo 8.7 (Treestar, Ashland, OR).
RNA extraction and mRNA expression
1–1.5 million cells were centrifuged and cell pellets were homogenised in TriReagent™(MBL) for total RNA, followed by storage at -80
οC. Total RNA extraction and cDNA synthesis were performed as previously described [
24]. Probe and primer sequences are summarized in Additional file
2: Table S1. GAPDH levels were used as endogenous control for the normalization of mRNA expression levels in BAL samples. Gene expression analysis was performed following incorporation of relative expression values in average (duplicates) normalized by GAPDH. Relative expression values for the patient cohort were calculated by 2-
ΔΔCt method, where ΔΔCt = (sample Ct GOI-sample Ct GAPDH)-(Calibrator Ct GOI- Calibrator Ct GAPDH), GOI = gene of interest, calibrator = mean of all Cts.
mtDNA/ gDNA ratio determination
Total DNA isolation from 10
4 to 10
5 BAL cells was performed using NucleoSpin Tissue (Macherey-Nagel) according to the manufacturer’s protocol. To quantify the mtDNA/gDNA ratio, qPCR was used to quantify the mitochondria DNA encoded genes ND1 and ND5 and the haemoglobin B1 gene. Primer sequences are included in Additional file
2: Table S1. Relative amounts of mitochondria DNA to HGB1 genomic sequence was calculated according to 2-
ΔΔCt method, where ΔΔCt = (sample Ct GOI-sample Ct HGB1)-(Calibrator Ct GOI- Calibrator Ct HGB1), GOI = gene of interest ie ND1 or ND5, calibrator = mean of all Cts.
Western blot analysis
1–1.5 million cells were centrifuged and cell pellets were homogenised in RIPA buffer (Invitrogen) containing protease and phosphatase inhibitors, Pierce), followed by storage at -80οC. 40–60 μg Total protein lysates of BAL samples were separated in 12% SDS-PAGE, transferred to 0.45 nm nitrocellulose membrane (Biorad), followed by detection of PINK1[anti-PINK1, mouse monoclonal antibody, (Novus Biologicals)], TOMM20 [anti-TOMM20, rabbit polyclonal (Abnova)], p62 [anti-p62 mouse monoclonal antibody (MBL)], LC3 [anti-LC3 mouse monoclonal antibody (Abgent)] and b-actin [anti-b-actin mouse monoclonal antibody (Sigma)]. Appropriate anti-mouse HRP conjugated secondary antibody (Chemicon) was used and immunodetection was performed with enhanced chemiluminescence reagent Luminata™ (Millipore). Bands were visualised with the ChemiDocXRS+ system (Biorad) and densitometry analyses were performed using Image Lab™ software (Biorad).
Immunofluorescence
Permeabilisation buffer (0.5%FBS, 0.2%Triton in TBS) was added for 10 min followed by blocking buffer (0.5%FBS, 0.1%Triton, 2 mg/ml BSA in TBS) for 10 min at room temperature. Primary antibody incubations were carried out for 60 min at room temperature followed by washing with TBS. Secondary antibody incubations were performed for 30 min followed by washing with TBS. ToPro or DAPI was added for nuclear staining. Finally, TrueBlack (Biotium) was added for 30 s so as to eliminate autofluorescence signal due to intracellular lipofuscin granules. Images were taken by Leica confocal microscope. Mean intensity of protein levels/cell was performed with ImageJ v2.0.0-rc-69/1.52i. Colocalization of mitochondria with autophagosomes or lysosomes was analysed by coloc2 plugin of Image J software.
Lysosome inhibition for autophagy and mitophagy flux measurements
BAL cells were plated on glass slides or plastic dishes for 1 h as described above. Following removal of non-adherent cells, AMs were treated with 0.1 mM chloroquine, for 30 min and fixed with 4% formaldehyde for 20 min followed by washing with PBS for immunofluorescence analysis or lysed in RIPA buffer for western blot analyses.
Statistical analysis
Data were analyzed using Prism 5 (Graph Pad) software and comparisons were made by t test, Mann-Whitney test, or chi-square test, as appropriate. Spearman’s correlation coefficient (r) analysis measured the association between two variables. A p value less than 0.05 was considered statistically significant (*p < 0.05, **p < 0.01, ***p < 0.001).
Discussion
Impaired mitochondria homeostasis and function are established hallmarks of aging and contribute to cell senescence, chronic inflammation and age-dependent decline in stem cell activity [
27] while age associated changes have been linked to IPF pathogenesis [
3,
28]. In this study, we used BAL, a tool for both clinical and research purposes [
29,
30], and a rich source of AMs. We showed that mitochondria in AMs from IPF patients have prominent morphological defects and impaired transcription. We observed a significant reduction of mitochondria homeostasis regulators PINK1, PARK2 and NRF1. Additionally, a significant increase in mtROS was associated with reduced expression of mitochondria-encoded OXPHOS genes.
PINK1 plays a significant role in mitochondria homeostasis via mitophagy dependent and independent pathways [
31]. A decrease in PINK1 levels in type II AECs from IPF patients, IPF lung tissue, aging mice and mice challenged with bleomycin has been associated with the development of fibrosis [
9‐
12,
32]. PINK1-knockout results in increased mtROS production, mitochondria fragmentation/fission and activation of autophagy, prompting the clearance of oxidized mitochondria [
9,
33]. We demonstrated a significant decrease in PINK1 levels, coupled to lower PARK2 transcription, in IPF AMs. Consistently with decreased PINK1 and increased mtROS, morphological characteristics of mitochondria, including prominent association with vesicular structures, swollen, irregular shapes, shorter length, and disorganized cristae, suggestive of mitochondrial fission, were also observed.
The accumulation of oxidized mitochondria could be attributed to a dysregulation of mitochondria quality control mechanism that includes clearance of damaged mitochondria mainly via mitophagy [
34]. Autophagosome formation and LC3B activation were previously shown reduced in IPF lungs and following TGF-βtreatment [
35], while fibroblast foci show elevated activation of mTOR, suggesting a downregulation of autophagy [
36]. However, a survival mechanism of pro-fibrotic AMs via increased LC3B-dependent mitophagy of PINK1 associated mitochondria has been previously demonstrated [
37]. In our study, the endogenous levels of LC3B II were quite prominent in several samples suggesting the presence of the lipid-associated form of LC3B in AMs from both controls and IPF. We did not observe increased levels of LC3B II in IPF as previously shown [
37], while autophagy flux was similar in the two groups. Furthermore, we assessed mitophagy levels by the degree of colocalization of LC3B puncta with mitochondrial protein TOMM20 and no significant differences were observed. Interestingly, we observed a significant increase in lysosomal degradation of TOMM20 in IPF cells. Conceivably, the increased levels of mitochondria degradation could be attributed to increased phagocytosis of cell free mitochondria accumulated in BAL [
26]. Alternatively, our results may reflect an imbalance in mitochondria biogenesis and degradation, since a recent study has shown that the biogenesis of mitochondria is also defective in IPF [
11]. Additionally, other mitochondria clearance mechanisms have been described such as mitochondria derived vesicles and spheroids that drive mitochondria lysosomal degradation independent of the classic autophagy pathway and may play a role in IPF [
38].
Furthermore, mtROS was significantly increased and associated with increased age and diminished lung function in IPF, suggesting a correlation with disease severity. Persistently increased mtROS, has been associated with mitochondria damage that could blunt macrophage activation and function. Indeed, increased basal levels of mtROS in Chronic Obstructive Pulmonary Disease (COPD) resulted in lower acute mtROS production upon bacterial infection leading to reduced apoptosis and bactericidal activity of AMs [
39]. Notably, the persistently increased mtROS in IPF AMs described in this study may explain previous observations showing that innate immune responses such as NLRP3 inflammasome activation and antiviral gene expression are altered in the BAL cells of IPF patients [
40,
41].
Immune cell functions including macrophage plasticity are largely shaped by mitochondria activity and cellular metabolism [
4,
42]. Activation of Toll-like receptors, such as TLR4, leads to a switch from OXPHOS to glycolysis in immune cells, similar to that occurring in tumors [
43] whereas macrophages activated with IL-4 commit to OXPHOS and fatty acid oxidation (FAO) showing minimal metabolic adaptation when compared to homeostasis [
42]. Two populations of AMs exist in the injured lung, resident AMs, and recruited AMs that originate from circulating monocytes. Recruited AMs produce inflammatory cytokines in association with increased glycolytic and arginine metabolism whereas resident AMs proliferate locally and are characterized by increased tricarboxylic acid cycle and amino acid metabolism [
44]. Pro-fibrotic mouse AMs showed an increase in glycolysis and glycolytic enzyme transcription, but no dependence on FAO or OXPHOS [
45]. Importantly, reversal of macrophage phenotype by 2-deoxy-D-glucose, an inhibitor of glycolysis was shown to reduce fibrosis in the same study [
45]. To date, there are no reports of macrophage metabolic profiles from IPF patients. Interestingly, expression of MRC I and V mt-encoded OXPHOS genes was significantly reduced in IPF BAL cells. In addition, the NRF1 transcription factor that regulates mt-respiratory gene expression and mitochondria biogenesis [
46] was significantly downregulated in IPF. Intriguingly, loss of PINK1 also results in decreased MRC complex 1 activity independently of mitophagy [
47]. Therefore, our results may suggest a decrease in mitochondria respiratory activity in IPF alveolar macrophages.
According to the previous paradigm of macrophage categorisation into classical/proinflammatory, alternative/resolving and pro-repair/fibrotic population, alternatively activated macrophages were suggested to predominate in IPF as indicated by the increased surface expression of manose receptor CD206 [
48]. In our study, the levels of CD45
+CD11c
+CD163
+ alveolar macrophages were significantly higher in IPF BAL. Recent studies propose that a diverse population of macrophages exists in IPF lungs with both pro-inflammatory and pro-fibrotic gene expression [
18,
19,
49,
50]. Further studies are required to elucidate the phenotypic and functional characteristics of the AM population in the BAL showing increased mtROS.
Some limitations of our study should be considered, mainly regarding the differences in the number of patients included in each experiment, which is based on the number of cells required for each method, and the diversity in total cell count of cells in each BAL sample. However, it needs to be stressed that patients were randomly selected for each method, and furthermore, mtROS levels were evaluated in most patients included in the study.
The impact of dysregulated mitochondrial complex expression and increased oxidation levels on the antimicrobial action of lung macrophages in health and disease has been recently described [
51‐
53]. Furthermore, the association of increased mtROS with aging, a major cofactor in the development of IPF was evident in this series of patients. Our study provides novel findings about mitochondrial gene expression, morphology, and oxidation levels, in alveolar macrophages in IPF that could be indirectly linked with IPF pathogenesis and disease progression. Conclusively, we report that AMs in IPF accumulate oxidized and dysmorphic mitochondria, which correlated with clinical variables of the disease. Impaired mitochondria activity may provide a better understanding of AMs activation in IPF. Importantly, targeted antioxidant therapies may need re-evaluation in IPF with respect to macrophage functions.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.